Stockscreener 앱 받기
0.8951
4.14%
0.0356
시장 영업 전:
.89
-0.0051
-0.57%
전일 마감가:
$0.8595
열려 있는:
$0.83
하루 거래량:
550.81K
Relative Volume:
0.32
시가총액:
$5.25M
수익:
$4.70M
순이익/손실:
$-4.99M
주가수익비율:
-0.1394
EPS:
-6.42
순현금흐름:
$-5.29M
1주 성능:
-3.23%
1개월 성능:
-72.03%
6개월 성능:
-92.35%
1년 성능:
-95.88%
1일 변동 폭
$0.83
$0.915
1주일 범위
$0.8101
$0.97
52주 변동 폭
$0.7106
$108.00
Salarius Pharmaceuticals Inc Stock (SLRX) Company Profile
명칭
Salarius Pharmaceuticals Inc
전화
346-772-0346
주소
2450 HOLCOMBE BLVD, HOUSTON
SLRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SLRX
Salarius Pharmaceuticals Inc
|
0.8951 | 5.04M | 4.70M | -4.99M | -5.29M | -6.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Salarius Pharmaceuticals Inc Stock (SLRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-04-27 | 개시 | Ladenburg Thalmann | Buy |
Salarius Pharmaceuticals Inc 주식(SLRX)의 최신 뉴스
Can Salarius Pharmaceuticals Inc. (FP10) stock resist broad market declinesTrend Reversal & Accurate Entry/Exit Alerts - Newser
Why Salarius Pharmaceuticals Inc. stock is a must watch in 2025Weekly Market Summary & Fast Entry High Yield Tips - Newser
Salarius Pharmaceuticals Inc. (SLRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Is Salarius Pharmaceuticals Inc. stock attractive for income investorsProduct Launch & Daily Entry Point Alerts - Newser
Can Salarius Pharmaceuticals Inc. (FP10) stock sustain breakout momentumJuly 2025 Reactions & AI Powered Market Entry Ideas - Newser
How Salarius Pharmaceuticals Inc. (FP10) stock responds to job market shiftsWeekly Volume Report & Smart Money Movement Alerts - Newser
Salarius Pharmaceuticals, Inc. (SLRX) 7.9% in After-hours: Collaboration with Texas Biomedical Research Institute Sparks Interest - Stocks Telegraph
Salarius Pharmaceuticals' Decoy Unit Partners With Texas Biomed on Flu Inhibitor Testing - MarketScreener
Salarius Pharmaceuticals to collaborate with Texas Biomedical Research Institute on avian flu study - marketscreener.com
SLRX Collaborates with Texas Research Institute for Influenza Te - GuruFocus
Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study - GlobeNewswire
Will Salarius Pharmaceuticals Inc. stock benefit from infrastructure spending2025 Trade Ideas & AI Forecasted Entry and Exit Points - moha.gov.vn
Is Salarius Pharmaceuticals Inc. stock affected by interest rate hikes2025 Price Action Summary & Consistent Profit Trading Strategies - moha.gov.vn
Hanish of Salarius Pharma buys $3740 in shares By Investing.com - Investing.com South Africa
Hanish of Salarius Pharma buys $3740 in shares - Investing.com India
[Form 4] Salarius Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
What analysts say about Salarius Pharmaceuticals Inc stockDividend Yield Trends & Technical + Fundamental = Smarter Investing - earlytimes.in
Salarius Pharmaceuticals Inc (SLRX) can make a big difference with a little luck - Setenews
[Form 3] Salarius Pharmaceuticals, Inc. Initial Statement of Beneficial Ownership - Stock Titan
SLRX Stock Institutional Owners - Quiver Quantitative
How Salarius Pharmaceuticals Inc. stock reacts to inflationary pressuresJuly 2025 PostEarnings & Free AI Powered Buy and Sell Recommendations - newser.com
Salarius Pharmaceuticals Exec VP Finance, CFO Mark J Rosenblum Acquires 20,000 Shares - TradingView
Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol SLRX - MarketScreener
Why Salarius Pharmaceuticals Inc. (FP10) stock stays resilientJuly 2025 Intraday Action & AI Enhanced Market Trend Forecasts - newser.com
Salarius clarifies Nasdaq listing status, refutes S&P CapIQ error By Investing.com - Investing.com India
Salarius Pharmaceuticals (NASDAQ:SLRX) Stock Price Down 8.3% – Here’s Why - Defense World
Will Salarius Pharmaceuticals Inc. (FP10) stock benefit from infrastructure bill - newser.com
Ranking Salarius Pharmaceuticals Inc. among high performing stocks via toolsProduct Launch & Stepwise Entry/Exit Trade Alerts - newser.com
When is the best time to exit Salarius Pharmaceuticals Inc.Market Trend Summary & Free Weekly Watchlist of Top Performers - newser.com
What catalysts could drive Salarius Pharmaceuticals Inc. stock higher - newser.com
Applying Elliott Wave Theory to Salarius Pharmaceuticals Inc.Portfolio Profit Report & Low Risk Profit Maximizing Plans - newser.com
[8-K] Salarius Pharmaceuticals, Inc. Reports Material Event | SLRX SEC FilingForm 8-K - Stock Titan
Salarius Pharmaceuticals Says S&P Capital IQ Platform Misreported Nasdaq Status After Merger - marketscreener.com
Salarius Pharmaceuticals (SLRX) Maintains Nasdaq Listing Despite Reporting Error - GuruFocus
Salarius clarifies Nasdaq listing status, refutes S&P CapIQ error - Investing.com
Trend analysis for Salarius Pharmaceuticals Inc. this weekWeekly Risk Report & Advanced Swing Trade Entry Plans - newser.com
Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol 'SLRX” - The Manila Times
Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX” - marketscreener.com
Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform - GlobeNewswire
Salarius Pharmaceuticals Inc (SLRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.10%
1.10%
자본화:
|
볼륨(24시간):